Literature DB >> 18983776

[Etiological analysis of 1977 patients with acute liver failure, subacute liver failure and acute-on-chronic liver failure].

Xiao-yan Liu1, Jin-hua Hu, Hui-fen Wang, Ju-mei Chen.   

Abstract

OBJECTIVE: To investigate the etiology of 1977 patients from northern China with acute (ALF), sub-acute (SALF) or acute-on-chronic liver (ACLF) failures.
METHOD: The age, gender, etiology, pathogenesis, and prognosis of the 1977 patients with liver failures were retrospectively analyzed.
RESULTS: Of the 1977 cases, the three most common causes of ALF were HEV (33.96%) or HBV (13.21%) infections or those caused by medicines (9.43%). The three predominant causes of SALF were medicines (31.53%), HEV (16.22%) or HBV (9.91%) infections, but those of the ACLF were HBV (90.29%) infection, alcoholic hepatopathy (2.65%), and HBV super infected with HEV (2.26%) infections. 90.09% (1781) patients were infected by hepatotropic viruses. Of these 1781 patients, the most common cause of their liver failures was HBV infection (92.93%). In these HBV infected patients, 77.10% were from 26 to 55 years old. From 2005 to 2007, there were 39 patients with alcoholic liver failure. In the past two years, there were 23 patients with drug induced liver failure. The improvement rate of the 1977 patients after their treatments was 35.56%. The improvement rate of HEV infected liver failure was higher than drug induced liver failure (P less than 0.05); no statistical significance was found between other groups (P more than 0.05).
CONCLUSION: Different types of liver failure have different predominant causes. HBV infection is the most common cause in our 1977 patients. In the past two years, the number of drug induced liver failures and alcoholic liver failures have been increasing.

Entities:  

Mesh:

Year:  2008        PMID: 18983776

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  7 in total

1.  Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Su-Jun Zheng; Shuang Liu; Mei Liu; Malcolm A McCrae; Jun-Feng Li; Yuan-Ping Han; Chun-Hui Xu; Feng Ren; Yu Chen; Zhong-Ping Duan
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.

Authors:  Yang Zhang; Xiao-Yu Hu; Sen Zhong; Fang Yang; Tao-You Zhou; Guo Chen; Yan-Yan Wang; Jian-Xing Luo
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

3.  Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Kun Huang; Jin-Hua Hu; Hui-Fen Wang; Wei-Ping He; Jing Chen; Xue-Zhang Duan; Ai-Min Zhang; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

4.  A Dual Role of Complement Activation in the Development of Fulminant Hepatic Failure Induced by Murine-Beta-Coronavirus Infection.

Authors:  Yingying Fang; Yan Guo; Tongtong Gao; Xuelian Han; Yuting Jiang; Min Li; Wei Xue; Binhui Yang; Yujun Cui; Shihui Sun; Guangyu Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-04-29       Impact factor: 6.073

5.  Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure.

Authors:  Yuting Chen; Jingkang Sun; Xiude Fan; Xiaoyun Wang; Lu Zeng; Xiaoge Zhang; Kun Zhang; Na Li; Qunying Han; Zhengwen Liu
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

6.  Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure.

Authors:  Yun-Hao Xun; Jun-Ping Shi; Chun-Qing Li; Dan Li; Wei-Zhen Shi; Qing-Chun Pan; Jian-Chun Guo; Guo-Qing Zang
Journal:  Mol Med Rep       Date:  2014-02-25       Impact factor: 2.952

7.  Changing etiologies and outcome of liver failure in Southwest China.

Authors:  Gui-Juan Xie; Hui-Yan Zhang; Qing Chen; Hui-Min Liu; Jian-Ping You; Sha Yang; Qing Mao; Xu-Qing Zhang
Journal:  Virol J       Date:  2016-06-04       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.